Diligence memo · auto-generated · as of July 2, 2026
Xeris Pharmaceuticals Inc
Xeris Pharmaceuticals Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Xeris Pharmaceuticals Inc operates in Pharmaceuticals, based in Chicago.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Xeris Pharmaceuticals Inc has raised $86M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2015-12-31.
Most recent recorded round closed around 2017-05-17.
Valuation (modeled)modeled
Provath models Xeris Pharmaceuticals Inc at approximately $1.1B (range $98M–$2.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.45× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 9.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.